Brief: Actinium Announces Nih Grant Extension To Advance Clinical Development Of Cd45 Targeted Conditioning Agent Iomab-Act With Memorial Sloan Kettering's Car-T Cell Therapy
04/10/2023 12:39
Oct 4 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ANNOUNCES NIH GRANT EXTENSION TO ADVANCE CLINICAL
DEVELOPMENT OF NEXT-GENERATION CD45 TARGETED CONDITIONING AGENT
IOMAB-ACT WITH MEMORIAL SLOAN KETTERING'S CAR-T CELL THERAPY
Source text for Eikon: ID:nPn72dF6Xa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities